Shanghai OPM Biosciences (688293)2025-01-17 10:55Financial Performance - The company expects a net profit attributable to shareholders of approximately 20.33 million yuan for 2024, a decrease of about 33.71 million yuan or 62.37% compared to the previous year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be around 5.79 million yuan, a decrease of about 28.94 million yuan or 83.33% year-on-year[2]. - In 2023, the total profit was 61.67 million yuan, and the net profit attributable to shareholders was 54.04 million yuan[4][5]. - The basic earnings per share for 2023 were 0.47 yuan per share[6]. Revenue and Sales Growth - The company achieved over 40% growth in product sales revenue in 2024, with an increase exceeding 50% after excluding last year's revenue from transferring culture medium formulas[7]. Tax and Expenses - The company incurred an increase in income tax expenses of 6.86 million yuan due to the cancellation of its high-tech enterprise qualification, raising the corporate income tax rate from 15% to 25%[8]. - Asset impairment losses significantly impacted the company's performance in 2024, with total impairment losses amounting to 16.95 million yuan[10]. Future Prospects - The "Aopu Mai CDMO Biopharmaceutical Commercial Production Platform" commenced operations in 2024, contributing to future growth despite initial high fixed costs[7]. - The company is actively preparing to reapply for high-tech enterprise qualification after the cancellation of its previous status[9]. - The company has not identified any significant uncertainties that may affect the accuracy of this earnings forecast[11].